文献速递白血病

DNA甲基转移酶抑制剂与组蛋白去乙酰化酶抑制剂联合治疗急性髓系白血病细胞:以基因体去甲基化为主的相关协同基因下调

Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation.
PubMed 文献 · Leukemia · 2018-11-23

在U937细胞中,DAC与帕比司他或丙戊酸联合处理影响的转录本显著多于各单药调控基因数之和,显示全基因组表达量上的协同效应,且以下调基因尤为突出。整合甲基化组与转录组分析显示,包括MYC和KDM2B、SUV39H1在内的基因大幅下调主要与基因体DNA去甲基化及acH3K9/27变化相关。

要点

  • DAC联合帕比司他或丙戊酸对U937细胞全基因组表达的协同效应以下调基因尤为突出。
  • 包括MYC和KDM2B、SUV39H1在内的基因大幅下调主要与基因体DNA去甲基化及acH3K9/27变化相关。
  • 上述发现对联合表观遗传治疗的机制及临床试验中该方案的疗效理解有提示意义。

核心结论

  • DAC联合帕比司他或丙戊酸在U937细胞中产生全基因组表达量协同效应,以下调基因尤为突出;基因大幅下调主要与基因体DNA去甲基化及acH3K9/27变化相关。

研究设计与样本

  • 在U937细胞中进行转录组分析、整合甲基化组与转录组分析,比较DAC联合HDACi(帕比司他或丙戊酸)与单药处理的基因表达变化。

主要发现

  • DAC联合帕比司他或丙戊酸影响的转录本显著多于各单药调控基因数之和,显示全基因组表达量协同效应,以下调基因尤为突出。
  • 包括MYC和KDM2B、SUV39H1在内的基因大幅下调主要与基因体DNA去甲基化及acH3K9/27变化相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DNA methyltransferase inhibitors (DNMTi) approved for older AML patients are clinically tested in combination with histone deacetylase inhibitors (HDACi). The mechanism of action of these drugs is still under debate. In colon cancer cells, 5-aza-2'-deoxycytidine (DAC) can downregulate oncogenes and metabolic genes by reversing gene body DNA methylation, thus implicating gene body methylation as a novel drug target. We asked whether DAC-induced gene body demethylation in AML cells is also associated with gene repression, and whether the latter is enhanced by HDACi.Transcriptome analyses revealed that a combined treatment with DAC and the HDACi panobinostat or valproic acid affected significantly more transcripts than the sum of the genes regulated by either treatment alone, demonstrating a quantitative synergistic effect on genome-wide expression in U937 cells. This effect was particularly striking for downregulated genes. Integrative methylome and transcriptome analyses showed that a massive downregulation of genes, including oncogenes (e.g., MYC) and epigenetic modifiers (e.g., KDM2B, SUV39H1) often overexpressed in cancer, was associated predominantly with gene body DNA demethylation and changes in acH3K9/27. These findings have implications for the mechanism of action of combined epigenetic treatments, and for a better understanding of responses in trials where this approach is clinically tested.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Blagitko-Dorfs N, Schlosser P, Greve G, et al. Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation. Leukemia. 2018. PMID: 30470836. doi:10.1038/s41375-018-0293-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。